toxylact: a04ad04 chlorbutanol
The first professional lActological database in the word
Chlorobutanol and its combinations in ATC class A04AD04 are categorized as other antiemetics used for the symptomatic treatment of nausea and vomiting, but they are now mainly of historical and preservative interest and lack robust human data on use in pregnancy and lactation. In lactating or pregnant patients, chlorobutanol‑containing medicines should be approached with caution, favoring alternatives with better characterized reproductive safety whenever clinically feasible.perinatology+3
ATC A04AD04 overview
ATC class A04AD groups “other antiemetics” within the alimentary tract and metabolism system, distinct from dopamine antagonists, serotonin antagonists, and antihistamines. Within this class, A04AD04 designates chlorobutanol as a single‑substance antiemetic, and A04AD54 covers fixed combinations containing chlorobutanol. These codes are primarily of regulatory and classification relevance, as chlorobutanol no longer has widely recognized standalone systemic therapeutic indications.drugbank+2
Pharmacology and clinical use
Chlorobutanol (chloretone) is a tertiary alcohol, structurally related to chloral hydrate, with sedative‑hypnotic, weak local anesthetic, and antimicrobial properties (antibacterial and antifungal). It has historically been used as an oral sedative and as a topical anesthetic, but in contemporary practice its principal role is as a preservative in multi‑ingredient pharmaceutical formulations, including ophthalmic solutions and injectables, typically at concentrations around 0.5%. As an antiemetic within A04AD04, chlorobutanol has been used for symptomatic relief of nausea and vomiting, though modern antiemetic protocols rarely rely on it as a first‑line agent.medpedia.framar+4
Mechanistically, its sedative‑hypnotic effect is thought to contribute indirectly to antiemetic activity, while local anesthetic and mucosal effects may play a minor role. Its long terminal half‑life (around 37 days) leads to drug accumulation with repeated doses, which significantly restricts its use as a systemic sedative and raises concern for chronic exposure. Oral LD50 values in animals (e.g. ~510 mg/kg in rats) and in vitro toxicity to ocular surface cells underscore a meaningful margin for toxicity, especially outside dilute preservative concentrations.wikipedia+1
Toxicological profile
Reported adverse reactions to chlorobutanol include hypersensitivity reactions, CNS depression (weakness, loss of consciousness), and respiratory depression, largely consistent with sedative‑hypnotic pharmacology. Experimental data indicate potential toxicity to the liver, skin, and eyes, and significant conjunctival and corneal cell toxicity with topical formulations, particularly at higher concentrations or prolonged exposure. In clinical use, chlorobutanol is therefore handled as a potentially toxic excipient or active ingredient that warrants dose limitation and avoidance of unnecessary systemic exposure.medpedia.framar+2
From a broader toxicological perspective, chlorobutanol’s long half‑life, lipophilicity, and tissue accumulation raise theoretical concerns about chronic exposure in vulnerable populations, including pregnant and lactating patients and neonates. No robust human data define thresholds for organ toxicity in these groups, and chlorobutanol is not considered a preferred sedative, anesthetic, or antiemetic when safer alternatives exist.wikipedia+1
Pregnancy and lactation considerations
There are no well‑controlled human studies describing fetal risk, teratogenicity, or pregnancy outcomes specifically associated with chlorobutanol exposure. Contemporary regulatory and clinical guidance for medicines in pregnancy and breastfeeding emphasize individualized risk–benefit assessment, use of agents with reassuring human data when possible, and avoidance of statements that a medicine is “safe” without qualification—principles that are directly applicable to chlorobutanol. Because chlorobutanol has largely historical systemic use and acts mainly as a preservative at low concentrations, pregnancy and lactation labeling is typically limited or absent, and chlorobutanol‑containing products are rarely chosen intentionally for systemic antiemetic therapy in pregnant women.gov+3
In lactation, key parameters—milk concentrations, milk‑to‑plasma ratio, relative infant dose, and documented infant effects—are not well characterized for chlorobutanol. Given its sedative‑hypnotic properties and long half‑life, theoretical risks to breastfed infants include CNS and respiratory depression and cumulative exposure, especially in premature or medically fragile neonates. Current best practice is therefore to:perinatology+1
· Prefer antiemetics with established human lactation data (e.g. certain antihistamines, 5‑HT3 antagonists) when clinically appropriate.atcddd.fhi+1
· Avoid systemic chlorobutanol use in pregnant or lactating patients unless no suitable alternatives exist and benefits clearly outweigh the uncertain risks.ema.europa+1
· Recognize that low‑dose chlorobutanol used purely as a preservative in topical or ophthalmic preparations will likely result in minimal systemic exposure, but still document and consider cumulative sources.drugbank+2
Counseling should follow Pregnancy and Lactation Labeling Rule (PLLR) principles: document indication, dose, route, timing of exposure, and alternative agents reviewed; communicate that available data are limited and that chlorobutanol is not a preferred agent in pregnancy or breastfeeding.gov+2
Practical toxicological‑lactological guidance
For healthcare professionals, the toxicological‑lactological stance on ATC A04AD04 medicines (chlorobutanol and its combinations) can be summarized as cautious, non‑preferential use:
· Indication: Reserve systemic chlorobutanol‑containing antiemetics for situations where modern alternatives are unsuitable or unavailable, and where nausea or vomiting poses significant maternal or fetal risk.atcddd.fhi+1
· Dose and duration: Use the lowest effective dose for the shortest possible duration; avoid chronic or repeated courses due to accumulation and CNS toxicity potential.perinatology+1
· Pregnancy: Do not initiate or discontinue chlorobutanol solely because of pregnancy without a structured risk–benefit discussion, but actively consider switching to antiemetics with better characterized pregnancy safety.ema.europa+2
· Lactation: In breastfeeding women, weigh the benefits of continued therapy and breastfeeding against theoretical infant risks; in premature or high‑risk infants, prefer agents with defined lactation pharmacokinetics and safety data.ema.europa+1
· Monitoring: When exposure occurs, monitor mother and infant for signs of CNS and respiratory depression, allergic reactions, and ocular or hepatic toxicity, and document findings.medpedia.framar+2
An illustration: a breastfeeding mother with severe vomiting who cannot tolerate standard antiemetics should be evaluated for disease severity, alternative therapies, and infant vulnerability; if a chlorobutanol‑containing preparation is the only practical option, its use should be short‑term, documented, and accompanied by close infant observation for sedation or feeding difficulties.gov+2



